Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro

Clinical Cancer Research

Volumn 6, Issue 11, 2000, Pages 4409-4415

  Ikeda, Kazumasa ^a   Yoshisue, Kunihiro ^a   Matsushima, Eiji ^a   Nagayama, Sekio ^a   Kobayashi, Kaoru ^c   Tyson, Charles A ^b   Chiba, Kan ^c   Kawaguchi, Yasuro ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b SRI INTERNATIONAL   (United States)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN; CYTOCHROME P450 ISOENZYME; FLUOROURACIL; TEGAFUR;

ARTICLE; CANCER CHEMOTHERAPY; DRUG ACTIVATION; DRUG DEGRADATION; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; FLUOROURACIL; HUMANS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TEGAFUR;

EID: 0033739717     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Analogs of pyrimidine nucleosides. I. N1-(α-furanidyl) derivatives of natural pyrimidine bases and their antimetabolites
2. Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines
3. Tegafur/uracil + calcium folinate in colorectal cancer. Double modulation of fluorouracil
4. Antitumor activity and low intestinal toxicity of S-1, a new formation of oral tegafur, in experimental tumor models in rats
5. Recent developments in oral chemotherapy options for gastric carcinoma
6. The role of tegafur/uracil in pulmonary malignancy
7. Oral chemotherapy in head and neck cancer
8. Metabolic activation of ftorafur [R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: The microsomal oxidative pathway
9. Mechanism of action of ftorafur, a new antineoplastic agent
10. In vivo distribution and metabolism of N-1-(tetrahydrofuran-2-yl)-5-fluorouracil (FT-207)
11. Cytochrome P450 enzyme system: Genetic polymorphisms and impact on clinical pharmacology
12. Inhibition and induction of cytochrome P450 and the clinical implications
13. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry
14. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extract
15. Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O-deethylation in human liver microsomes
16. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
17. Liver microsomal cytochrome P-450-dependent O-dealkylation reaction in various animals
18. An improved assay of 7-ethoxycoumarin O-deethylase activity: Induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin
19. Purification and characterization of human liver microsomal cytochrome P-450 2A6
20. Mixed function oxidase and UDP-glucuronyltransferase activities in the human HEP G2 hepatoma cell line
21. Tolbutamide hydroxylation by human liver microsomes. Kinetics characterisation and relationship to other cytochrome P-450-dependent xenobiotic oxidations
22. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily
23. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography
24. Catalytic properties of the human cytochrome P450 2E1 produced by cDNA expression in mammalian cells
25. Bufuralol, dextromethorphan, and dehrisoquine as prototype substrates for human P450IID6
26. Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme
27. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
28. Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques
29. CYP2A6: A human coumarin 7-hydroxylase
30. Identification and characterization of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism
31. A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles
32. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase
33. Genetic polymorphism of CYP2A6 in the German population
34. Improvement of genotyping method of CYP2A6 gene and allelic frequency in Japanese
35. A new deleted allele in human cytochrome P450 2A6 (CYP2A6) gene found in human liver subjects showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thialidin-4-one hydrochloride (SM-12502)
36. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thialidin-4-one hydrochloride in humans
37. Characterization and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population
38. Genetic polymorphism of drug metabolizing enzymes: New mutations in CYP2D6 and CYP2A6 genes in Japanese
39. Deficient cotinine formation from cotinine is attributed to the whole deletion of the CYP2A6 gene in humans
40. Phase I and pharmacokinetic evaluation of UFT plus oral leucovorin
41. Hydroxylated metabolites of R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) in rats and rabbits
42. Activation of Ftorafur [R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and γ-butyrolactone
43. Methoxalen and coumarin interactions in man and mouse
44. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen
45. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers
46. Hepatic cytochrome P450 isozyme (CYP2A6 and CYP3A4) activities and fibrotic process in liver